Alzheon’s oral anti-amyloid drug has potential to be first oral Aβ-targeting therapy approved in US… EP News Bureau Apr 19, 2024 Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral,…
